Daniel O'Connell, MD, PhD, is a Partner at Novo Holdings and the Board Chair at Kivu Bioscience, where they leverage their extensive experience in healthcare investment and biotech. Previously, O'Connell served as an Investment Director at Arix Bioscience and an Executive Director at Bristol Myers Squibb, focusing on therapeutic opportunities and venture capital. They possess strong analytical skills, particularly in evaluating clinical data and regulatory strategies, and have a passion for addressing unmet medical needs through innovative therapeutics. O'Connell holds an MD/PhD in Biochemistry and Organic Chemistry from Tufts University School of Medicine, which they completed in 2012.
This person is not in the org chart
This person is not in any teams
This person is not in any offices